Spatial Multi-Omics Analysis Pipeline
Comprehensive biological interpretation of spatial omics data. Transforms spatially variable genes (SVGs), domain annotations, and tissue context into actionable biological insights covering pathway enrichment, cell-cell interactions, druggable targets, immune microenvironment, and multi-modal integration.
KEY PRINCIPLES:
- Report-first approach - Create report file FIRST, then populate progressively
- Domain-by-domain analysis - Characterize each spatial region independently before comparison
- Gene-list-centric - Analyze user-provided SVGs and marker genes with ToolUniverse databases
- Biological interpretation - Go beyond statistics to explain biological meaning of spatial patterns
- Disease focus - Emphasize disease mechanisms and therapeutic opportunities when disease context is provided
- Evidence grading - Grade all evidence as T1 (human/clinical) to T4 (computational)
- Multi-modal thinking - Integrate RNA, protein, and metabolite information when available
- Validation guidance - Suggest experimental validation approaches for key findings
- Source references - Every statement must cite tool/database source
- Completeness checklist - Mandatory section showing analysis coverage
- English-first queries - Always use English terms in tool calls. Respond in user's language
When to Use This Skill
Apply when users:
- Provide spatially variable genes from spatial transcriptomics experiments
- Ask about biological interpretation of spatial domains/clusters
- Need pathway enrichment analysis of spatial gene expression data
- Want to understand cell-cell interactions from spatial data
- Ask about tumor microenvironment heterogeneity from spatial omics
- Need druggable targets in specific spatial regions
- Ask about tissue zonation patterns (liver, brain, kidney)
- Want to integrate spatial transcriptomics + proteomics data
- Ask about immune infiltration patterns from spatial data
- Need to compare healthy vs disease regions spatially
- Ask "What pathways are enriched in this tumor core vs tumor margin?"
- Ask "What cell-cell interactions occur in this spatial domain?"
NOT for (use other skills instead):
- Single gene interpretation without spatial context -> Use
tooluniverse-target-research
- Variant interpretation -> Use
tooluniverse-variant-interpretation
- Drug safety profiling -> Use
tooluniverse-adverse-event-detection
- Disease-only analysis without spatial data -> Use
tooluniverse-multiomic-disease-characterization
- GWAS analysis -> Use
tooluniverse-gwas-* skills
- Bulk RNA-seq (non-spatial) -> Use
tooluniverse-systems-biology
Input Parameters
| Parameter |
Required |
Description |
Example |
| svgs |
Yes |
Spatially variable genes (gene symbols) |
['EGFR', 'CDH1', 'VIM', 'MYC', 'CD3E'] |
| tissue_type |
Yes |
Tissue/organ type |
brain, liver, lung, breast, skin |
| technology |
No |
Spatial omics platform used |
10x Visium, MERFISH, DBiTplus, SLIDE-seq |
| disease_context |
No |
Disease if applicable |
breast cancer, Alzheimer disease, liver cirrhosis |
| spatial_domains |
No |
Dict mapping domain name to marker genes |
{'Tumor core': ['MYC','EGFR'], 'Stroma': ['VIM','COL1A1']} |
| cell_types |
No |
Cell types identified in deconvolution |
['Epithelial', 'T cell', 'Macrophage', 'Fibroblast'] |
| proteins |
No |
Proteins detected (if multi-modal) |
['CD3', 'CD8', 'PD-L1', 'Ki67'] |
| metabolites |
No |
Metabolites detected (if SpatialMETA) |
['glutamine', 'lactate', 'ATP'] |
Spatial Omics Integration Score (0-100)
Score Components
Data Completeness (0-30 points):
- SVGs provided (>10 genes): 5 points
- Disease context provided: 5 points
- Spatial domains defined: 5 points
- Cell type composition available: 5 points
- Multi-modal data (protein/metabolite): 5 points
- Literature context found: 5 points
Biological Insight (0-40 points):
- Significant pathway enrichment (FDR < 0.05): 10 points
- Cell-cell interaction predictions: 10 points
- Disease mechanism identified: 10 points
- Druggable targets found in disease regions: 10 points
Evidence Quality (0-30 points):
- Cross-database validation (gene found in 3+ databases): 10 points
- Clinical validation (approved drugs for spatial targets): 10 points
- Literature support (PubMed evidence for spatial patterns): 10 points
Score Interpretation
| Score |
Tier |
Interpretation |
| 80-100 |
Excellent |
Comprehensive spatial characterization, strong biological insights, druggable targets identified |
| 60-79 |
Good |
Good pathway and interaction analysis, some disease/therapeutic context |
| 40-59 |
Moderate |
Basic enrichment complete, limited spatial domain comparison or interaction analysis |
| 0-39 |
Limited |
Minimal data, gene-level annotation only |
Evidence Grading System
| Tier |
Symbol |
Criteria |
Examples |
| T1 |
[T1] |
Direct human evidence, clinical proof |
FDA-approved drug for spatial target, validated biomarker |
| T2 |
[T2] |
Experimental evidence |
Validated spatial pattern in literature, known ligand-receptor pair |
| T3 |
[T3] |
Computational/database evidence |
PPI network prediction, pathway enrichment, expression correlation |
| T4 |
[T4] |
Annotation/prediction only |
GO annotation, text-mined association, predicted interaction |
Report Template
Create this file structure at the start: {tissue}_{disease}_spatial_omics_report.md
# Spatial Multi-Omics Analysis Report: {Tissue Type}
**Report Generated**: {date}
**Technology**: {platform}
**Tissue**: {tissue_type}
**Disease Context**: {disease or "Normal tissue"}
**Total SVGs Analyzed**: {count}
**Spatial Domains**: {count}
**Spatial Omics Integration Score**: (to be calculated)
---
## Executive Summary
(2-3 sentence synthesis of key spatial findings - fill after all phases complete)
---
## 1. Tissue & Disease Context
### Tissue Information
| Property | Value | Source |
|----------|-------|--------|
| Tissue type | | |
| Disease | | |
| Expected cell types | | HPA |
### Disease Identifiers (if applicable)
| System | ID | Source |
|--------|-----|--------|
**Sources**: (tools used)
---
## 2. Spatially Variable Gene Characterization
### 2.1 Gene ID Resolution
| Gene Symbol | Ensembl ID | Entrez ID | UniProt | Function | Source |
|-------------|------------|-----------|---------|----------|--------|
### 2.2 Tissue Expression Patterns
| Gene | Tissue Expression | Specificity | Source |
|------|-------------------|-------------|--------|
### 2.3 Subcellular Localization
| Gene | Location | Confidence | Source |
|------|----------|------------|--------|
### 2.4 Disease Associations
| Gene | Disease | Score | Evidence | Source |
|------|---------|-------|----------|--------|
**Sources**: (tools used)
---
## 3. Pathway Enrichment Analysis
### 3.1 STRING Functional Enrichment
| Category | Term | Description | P-value | FDR | Genes | Source |
|----------|------|-------------|---------|-----|-------|--------|
### 3.2 Reactome Pathway Analysis
| Pathway ID | Name | P-value | FDR | Genes Found | Total Genes | Source |
|------------|------|---------|-----|-------------|-------------|--------|
### 3.3 GO Biological Processes
| GO Term | Description | P-value | FDR | Genes | Source |
|---------|-------------|---------|-----|-------|--------|
### 3.4 GO Molecular Functions
| GO Term | Description | P-value | FDR | Genes | Source |
|---------|-------------|---------|-----|-------|--------|
### 3.5 GO Cellular Components
| GO Term | Description | P-value | FDR | Genes | Source |
|---------|-------------|---------|-----|-------|--------|
### Pathway Summary
- Top enriched pathways:
- Key biological processes:
- Spatial pathway implications:
**Sources**: (tools used)
---
## 4. Spatial Domain Characterization
### Domain: {domain_name}
#### Marker Genes
| Gene | Function | Pathways | Source |
|------|----------|----------|--------|
#### Enriched Pathways (domain-specific)
| Pathway | P-value | FDR | Genes | Source |
|---------|---------|-----|-------|--------|
#### Cell Type Signature
| Cell Type | Marker Genes Present | Confidence |
|-----------|---------------------|------------|
#### Biological Interpretation
(Narrative interpretation of this domain)
(Repeat for each domain)
### 4.N Domain Comparison
| Feature | Domain 1 | Domain 2 | Domain 3 |
|---------|----------|----------|----------|
| Top pathway | | | |
| Cell types | | | |
| Disease relevance | | | |
**Sources**: (tools used)
---
## 5. Cell-Cell Interaction Inference
### 5.1 Protein-Protein Interactions (STRING)
| Protein A | Protein B | Score | Type | Source |
|-----------|-----------|-------|------|--------|
### 5.2 Ligand-Receptor Pairs
| Ligand | Receptor | Domain (Ligand) | Domain (Receptor) | Evidence | Source |
|--------|----------|-----------------|-------------------|----------|--------|
### 5.3 Signaling Pathways
| Pathway | Components in Data | Spatial Distribution | Source |
|---------|--------------------|---------------------|--------|
### 5.4 Interaction Network Summary
- Key interaction hubs:
- Cross-domain interactions:
- Predicted cell-cell communication axes:
**Sources**: (tools used)
---
## 6. Disease & Therapeutic Context
### 6.1 Disease Gene Overlap
| Gene | Disease Association Score | Evidence Type | Source |
|------|--------------------------|---------------|--------|
### 6.2 Druggable Targets in Spatial Domains
| Gene | Domain | Tractability | Modality | Approved Drugs | Source |
|------|--------|-------------|----------|----------------|--------|
### 6.3 Drug Mechanisms Relevant to Spatial Targets
| Drug | Target | Mechanism | Phase | Source |
|------|--------|-----------|-------|--------|
### 6.4 Clinical Trials
| NCT ID | Title | Target Gene | Phase | Status | Source |
|--------|-------|-------------|-------|--------|--------|
### Therapeutic Summary
- Druggable genes in disease regions:
- Approved therapies:
- Pipeline drugs:
- Novel opportunities:
**Sources**: (tools used)
---
## 7. Multi-Modal Integration
### 7.1 Protein-RNA Concordance (if protein data available)
| Gene/Protein | RNA Pattern | Protein Pattern | Concordance | Source |
|-------------|-------------|-----------------|-------------|--------|
### 7.2 Subcellular Context
| Gene | mRNA Location (spatial) | Protein Location (HPA) | Concordance | Source |
|------|------------------------|----------------------|-------------|--------|
### 7.3 Metabolic Context (if metabolomics available)
| Gene | Metabolic Pathway | Metabolites Detected | Spatial Pattern | Source |
|------|-------------------|---------------------|-----------------|--------|
**Sources**: (tools used)
---
## 8. Immune Microenvironment (if relevant)
### 8.1 Immune Cell Markers
| Cell Type | Marker Genes | Spatial Domain | Source |
|-----------|-------------|----------------|--------|
### 8.2 Immune Checkpoint Expression
| Checkpoint | Gene | Expression Pattern | Source |
|------------|------|--------------------|--------|
### 8.3 Tumor-Immune Interface (if cancer)
| Feature | Finding | Evidence | Source |
|---------|---------|----------|--------|
### Immune Summary
- Immune infiltration pattern:
- Key immune checkpoints:
- Immunotherapy implications:
**Sources**: (tools used)
---
## 9. Literature & Validation Context
### 9.1 Literature Evidence
| PMID | Title | Relevance | Year | Source |
|------|-------|-----------|------|--------|
### 9.2 Known Spatial Patterns
(Known tissue architecture/zonation from literature)
### 9.3 Validation Recommendations
| Priority | Gene/Target | Method | Rationale |
|----------|-------------|--------|-----------|
| High | | IHC / smFISH | |
| Medium | | IF / ISH | |
**Sources**: (tools used)
---
## Spatial Omics Integration Score
| Component | Points | Max | Details |
|-----------|--------|-----|---------|
| SVGs provided | | 5 | |
| Disease context | | 5 | |
| Spatial domains | | 5 | |
| Cell types | | 5 | |
| Multi-modal data | | 5 | |
| Literature context | | 5 | |
| Pathway enrichment | | 10 | |
| Cell-cell interactions | | 10 | |
| Disease mechanism | | 10 | |
| Druggable targets | | 10 | |
| Cross-database validation | | 10 | |
| Clinical validation | | 10 | |
| Literature support | | 10 | |
| **TOTAL** | | **100** | |
**Score**: XX/100 - [Tier]
---
## Completeness Checklist
- [ ] Gene ID resolution complete
- [ ] Tissue expression patterns analyzed (HPA)
- [ ] Subcellular localization checked (HPA)
- [ ] Pathway enrichment complete (STRING + Reactome)
- [ ] GO enrichment complete (BP + MF + CC)
- [ ] Spatial domains characterized individually
- [ ] Domain comparison performed
- [ ] Protein-protein interactions analyzed (STRING)
- [ ] Ligand-receptor pairs identified
- [ ] Disease associations checked (OpenTargets)
- [ ] Druggable targets identified (OpenTargets tractability)
- [ ] Drug mechanisms reviewed
- [ ] Multi-modal integration performed (if data available)
- [ ] Immune microenvironment characterized (if relevant)
- [ ] Literature search completed
- [ ] Validation recommendations provided
- [ ] Spatial Omics Integration Score calculated
- [ ] Executive summary written
- [ ] All sections have source citations
---
## References
### Data Sources Used
| # | Tool | Parameters | Section | Items Retrieved |
|---|------|------------|---------|-----------------|
### Database Versions
- OpenTargets: (current)
- STRING: v12.0
- Reactome: (current)
- HPA: (current)
- GTEx: v10
Phase 0: Input Processing & Disambiguation (ALWAYS FIRST)
Objective: Parse user input, resolve tissue/disease identifiers, establish analysis context.
Tools Used
OpenTargets_get_disease_id_description_by_name (if disease context provided):
- Input:
diseaseName (string) - Disease name
- Output:
{data: {search: {hits: [{id, name, description}]}}}
- Use: Get MONDO/EFO IDs for disease queries
OpenTargets_get_disease_description_by_efoId:
- Input:
efoId (string) - Disease ID (e.g., MONDO_0007254)
- Output:
{data: {disease: {id, name, description, dbXRefs}}}
- Use: Get full disease description
HPA_search_genes_by_query (tissue cell type context):
- Input:
query (string) - Search term
- Output: List of gene entries matching query
- Use: Verify tissue-relevant genes
Workflow
- Parse SVG list from user input (ensure valid gene symbols)
- Identify tissue type and map to standard ontology term
- If disease provided, resolve to MONDO/EFO ID using OpenTargets
- Get disease description and cross-references
- Determine analysis scope:
- Cancer? -> Include immune microenvironment, somatic mutations, druggable targets
- Neurological? -> Include brain region specificity, neuronal markers
- Metabolic? -> Include metabolic zonation, enzyme distribution
- Normal tissue? -> Focus on tissue architecture and cell type composition
- Set up report file with header information
Decision Logic
- Cancer tissue: Enable immune microenvironment phase, CIViC/cBioPortal queries, immuno-oncology analysis
- Normal tissue: Skip disease phases, focus on tissue zonation and cell type composition
- Liver/kidney/brain: Enable zonation-specific analysis
- No disease context: Proceed with tissue biology only
- Small gene list (<20): Warn about limited enrichment power, emphasize gene-level analysis
- Large gene list (>500): Suggest filtering to top SVGs by significance before enrichment
Phase 1: Gene Characterization
Objective: Resolve gene identifiers, annotate functions, tissue specificity, and subcellular localization.
Tools Used
MyGene_query_genes (gene ID resolution):
- Input:
query (string) - Gene symbol
- Output:
{hits: [{_id, symbol, name, ensembl: {gene}, entrezgene}]}
- Use: Resolve gene symbol to Ensembl ID, Entrez ID
- NOTE: First hit may not be exact match - filter by
symbol field
UniProt_get_function_by_accession (gene function):
- Input:
accession (string) - UniProt accession
- Output: List of function description strings
- Use: Get protein function annotation
UniProt_get_subcellular_location_by_accession (protein localization):
- Input:
accession (string)
- Output: Subcellular location information
- Use: Where the protein is located in the cell
HPA_get_subcellular_location (validated localization):
- Input:
gene_name (string) - Gene symbol
- Output:
{gene_name, main_locations: [], additional_locations: [], location_summary}
- Use: Experimentally validated protein subcellular location
HPA_get_rna_expression_by_source (tissue expression):
- Input:
gene_name (string), source_type (string: 'tissue'), source_name (string)
- Output:
{data: {gene_name, source_type, source_name, expression_value, expression_level}}
- Use: Check expression in the specific tissue of interest
- NOTE: All 3 parameters are REQUIRED
HPA_get_comprehensive_gene_details_by_ensembl_id (full HPA data):
- Input:
ensembl_id (string), include_isoforms (bool), include_images (bool), include_antibodies (bool), include_expression (bool) - ALL 5 parameters REQUIRED
- Output:
{ensembl_id, gene_name, uniprot_ids, summary, protein_classes, tissue_expression, cell_line_expression, ...}
- Use: One-stop gene characterization from HPA
- NOTE: Use
include_expression=True for tissue data; set others to False for faster response
HPA_get_cancer_prognostics_by_gene (cancer prognosis):
- Input:
ensembl_id (string) - Ensembl gene ID (NOT gene_name)
- Output:
{gene_name, prognostic_cancers_count, prognostic_summary: [{cancer_type, prognostic_type, p_value}]}
- Use: Prognostic significance in cancer (if cancer context)
UniProtIDMap_gene_to_uniprot (ID mapping):
- Input:
gene_name (string), organism (string, default 'human')
- Output: UniProt accession for the gene
- Use: Map gene symbol to UniProt accession
Workflow
- For each SVG (batch if >20, sample top genes):
a. Query MyGene to get Ensembl ID, Entrez ID
b. Map to UniProt accession
c. Get subcellular location from HPA
d. Get tissue expression from HPA
e. If cancer: check cancer prognostics
- Compile gene characterization table
- Identify genes with tissue-specific expression
- Note genes with nuclear vs membrane vs secreted localization (relevant for spatial patterns)
Batch Strategy for Large Gene Lists
- 10-50 genes: Characterize all individually
- 50-200 genes: Characterize top 50 by priority (known disease genes first), summarize rest
- 200+ genes: Characterize top 30, use enrichment for the full list
- Always run pathway enrichment on the FULL list regardless
Phase 2: Pathway & Functional Enrichment
Objective: Identify biological pathways and functions enriched in SVGs and per-domain gene sets.
Tools Used
STRING_functional_enrichment (primary enrichment):
- Input:
protein_ids (array of gene symbols), species (int, 9606 for human)
- Output:
{status: 'success', data: [{category, term, number_of_genes, number_of_genes_in_background, p_value, fdr, description, inputGenes, preferredNames}]}
- Use: Comprehensive enrichment across GO, KEGG, Reactome, COMPARTMENTS, DISEASES
- Categories:
Process (GO:BP), Function (GO:MF), Component (GO:CC), KEGG, Reactome, COMPARTMENTS, DISEASES, Keyword, PMID
- NOTE: This is the PRIMARY enrichment tool. Returns all categories in one call
ReactomeAnalysis_pathway_enrichment (Reactome-specific):
- Input:
identifiers (string, space-separated gene symbols, NOT array)
- Output:
{data: {token, pathways_found, pathways: [{pathway_id, name, p_value, fdr, entities_found, entities_total}]}}
- Use: Detailed Reactome pathway analysis with hierarchy
- NOTE: identifiers is a SPACE-SEPARATED STRING, not array
Reactome_map_uniprot_to_pathways (individual gene):
- Input:
id (string) - UniProt accession
- Output: Plain list of pathway objects (no data wrapper)
- Use: Map individual proteins to Reactome pathways
GO_get_annotations_for_gene (individual gene GO):
- Input:
gene_id (string) - Gene symbol or ID
- Output: Plain list of GO annotation objects
- Use: Get GO annotations for individual genes
kegg_search_pathway (KEGG pathway search):
- Input:
query (string) - Pathway name or keyword
- Output: Pathway search results
- Use: Find KEGG pathways relevant to spatial findings
WikiPathways_search (WikiPathways):
- Input:
query (string) - Search term
- Output: WikiPathways search results
- Use: Additional pathway context
Workflow
- Global SVG enrichment: Run STRING_functional_enrichment on ALL SVGs
- Filter results by FDR < 0.05
- Separate by category (Process, Function, Component, KEGG, Reactome)
- Report top 10-15 per category
- Reactome detailed analysis: Run ReactomeAnalysis_pathway_enrichment
- Report top pathways with FDR < 0.05
- Per-domain enrichment (if spatial domains provided):
- Run STRING_functional_enrichment on each domain's gene set
- Compare enriched pathways across domains
- Identify domain-specific vs shared pathways
- Compile pathway tables: Merge results from all enrichment tools
Enrichment Interpretation
- Signaling pathways (RTK, Wnt, Notch, Hedgehog): Cell-cell communication
- Metabolic pathways: Tissue metabolic zonation
- Immune pathways: Immune infiltration/exclusion
- ECM/adhesion pathways: Tissue structure and remodeling
- Cell cycle/proliferation: Growth zones
- Apoptosis/stress: Damage zones
Phase 3: Spatial Domain Characterization
Objective: Characterize each spatial domain biologically and compare between domains.
Tools Used
Uses the same tools as Phase 2 (STRING_functional_enrichment, ReactomeAnalysis) applied per-domain, plus:
HPA_get_biological_processes_by_gene (per-gene processes):
- Input:
gene_name (string)
- Output: Biological processes associated with the gene
- Use: Annotate domain marker genes
HPA_get_protein_interactions_by_gene (gene interactions):
- Input:
gene_name (string)
- Output: Known protein interaction partners
- Use: Build domain-specific interaction context
Workflow
- For each spatial domain:
a. Get marker gene list
b. Run STRING_functional_enrichment on domain genes
c. Identify top pathways, GO terms
d. Assign likely cell type(s) based on marker genes:
- Epithelial: CDH1, EPCAM, KRT18, KRT19
- Mesenchymal/Fibroblast: VIM, COL1A1, COL3A1, FAP, ACTA2
- Immune T cell: CD3E, CD3D, CD4, CD8A, CD8B
- Immune B cell: CD19, CD20 (MS4A1), CD79A
- Macrophage: CD68, CD163, CSF1R
- Endothelial: PECAM1, VWF, CDH5
- Neuronal: SNAP25, SYP, MAP2, NEFL
- Hepatocyte: ALB, HNF4A, CYP3A4
e. Generate biological interpretation narrative
- Compare domains:
- Differential pathways
- Unique vs shared genes
- Disease-relevant vs homeostatic regions
- Transition zones (shared genes between adjacent domains)
Cell Type Assignment Rules
When user does not provide cell type annotations, infer from marker genes:
- Check each gene against known cell type markers
- Use HPA tissue/cell type expression data for validation
- Report confidence level (high: 3+ markers match, medium: 2 markers, low: 1 marker)
Phase 4: Cell-Cell Interaction Inference
Objective: Predict cell-cell communication from spatial gene expression patterns.
Tools Used
STRING_get_interaction_partners (PPI network):
- Input:
protein_ids (array), species (int, 9606), limit (int), confidence_score (float, 0.7)
- Output:
{status: 'success', data: [{preferredName_A, preferredName_B, score, nscore, fscore, pscore, ascore, escore, dscore, tscore}]}
- Use: Find protein-protein interactions among SVGs
- Score types: nscore=neighborhood, fscore=fusion, pscore=phylogenetic, ascore=coexpression, escore=experimental, dscore=database, tscore=textmining
STRING_get_protein_interactions (pairwise interactions):
- Input:
protein_ids (array), species (int, 9606)
- Output: Interaction data between specified proteins
- Use: Get interactions within a specific gene set
intact_search_interactions (IntAct database):
- Input:
query (string), max (int)
- Output: Interaction data from IntAct
- Use: Complement STRING with IntAct interactions
Reactome_get_interactor (Reactome interactions):
- Input: Protein/gene identifier
- Output: Reactome interaction data
- Use: Pathway-level interaction context
DGIdb_get_drug_gene_interactions (drug-gene interactions):
- Input:
genes (array of strings)
- Output: Drug-gene interaction data
- Use: Identify druggable interaction nodes
Ligand-Receptor Analysis
Known ligand-receptor pairs to check in SVG list:
- Growth factors: EGF-EGFR, HGF-MET, VEGF-KDR, FGF-FGFR, PDGF-PDGFRA/B
- Cytokines: TNF-TNFR, IL6-IL6R, IFNG-IFNGR, TGFB1-TGFBR1/2
- Chemokines: CXCL12-CXCR4, CCL2-CCR2, CXCL10-CXCR3
- Immune checkpoints: CD274(PD-L1)-PDCD1(PD-1), CD80/CD86-CTLA4, LGALS9-HAVCR2(TIM-3)
- Notch signaling: DLL1/3/4-NOTCH1/2/3/4, JAG1/2-NOTCH1/2
- Wnt signaling: WNT ligands-FZD receptors
- Adhesion: CDH1-CDH1 (homotypic), ITGA/B integrins-ECM
- Hedgehog: SHH-PTCH1
Workflow
- Run STRING_get_interaction_partners on all SVGs
- Filter interactions with score > 0.7
- Identify hub genes (most connections)
- Check for known ligand-receptor pairs in gene list
- Cross-reference with spatial domain assignments
- Identify potential cross-domain signaling
- Build interaction network:
- Intra-domain interactions (within same spatial region)
- Inter-domain interactions (between different regions)
- Identify signaling axes (e.g., tumor-stroma, immune-tumor)
- Map interactions to Reactome signaling pathways
Extended Reference: For detailed tool tables, examples, and templates, read REFERENCE.md in this skill directory.
The agent can access it via: read skills/tooluniverse-spatial-omics-analysis/REFERENCE.md
1---2name: tooluniverse-spatial-omics-analysis3description: Computational analysis framework for spatial multi-omics data integration. Given spatially variable genes (SVGs), spatial domain annotations, tissue type, and disease context from spatial transcriptomics/proteomics experiments (10x Visium, MERFISH, DBiTplus, SLIDE-seq, etc.), performs comprehensive biological interpretation including pathway enrichment, cell-cell interaction inference, druggable target identification, immune microenvironment characterization, and multi-modal integration. Produces a detailed markdown report with Spatial Omics Integration Score (0-100), domain-by-domain characterization, and validation recommendations. Uses 70+ ToolUniverse tools across 9 analysis phases. Use when users ask about spatial transcriptomics analysis, spatial omics interpretation, tissue heterogeneity, spatial gene expression patterns, tumor microenvironment mapping, tissue zonation, or cell-cell communication from spatial data.4---56# Spatial Multi-Omics Analysis Pipeline78Comprehensive biological interpretation of spatial omics data. Transforms spatially variable genes (SVGs), domain annotations, and tissue context into actionable biological insights covering pathway enrichment, cell-cell interactions, druggable targets, immune microenvironment, and multi-modal integration.910**KEY PRINCIPLES**:111. **Report-first approach** - Create report file FIRST, then populate progressively122. **Domain-by-domain analysis** - Characterize each spatial region independently before comparison133. **Gene-list-centric** - Analyze user-provided SVGs and marker genes with ToolUniverse databases144. **Biological interpretation** - Go beyond statistics to explain biological meaning of spatial patterns155. **Disease focus** - Emphasize disease mechanisms and therapeutic opportunities when disease context is provided166. **Evidence grading** - Grade all evidence as T1 (human/clinical) to T4 (computational)177. **Multi-modal thinking** - Integrate RNA, protein, and metabolite information when available188. **Validation guidance** - Suggest experimental validation approaches for key findings199. **Source references** - Every statement must cite tool/database source2010. **Completeness checklist** - Mandatory section showing analysis coverage2111. **English-first queries** - Always use English terms in tool calls. Respond in user's language2223---2425## When to Use This Skill2627Apply when users:28- Provide spatially variable genes from spatial transcriptomics experiments29- Ask about biological interpretation of spatial domains/clusters30- Need pathway enrichment analysis of spatial gene expression data31- Want to understand cell-cell interactions from spatial data32- Ask about tumor microenvironment heterogeneity from spatial omics33- Need druggable targets in specific spatial regions34- Ask about tissue zonation patterns (liver, brain, kidney)35- Want to integrate spatial transcriptomics + proteomics data36- Ask about immune infiltration patterns from spatial data37- Need to compare healthy vs disease regions spatially38- Ask "What pathways are enriched in this tumor core vs tumor margin?"39- Ask "What cell-cell interactions occur in this spatial domain?"4041**NOT for** (use other skills instead):42- Single gene interpretation without spatial context -> Use `tooluniverse-target-research`43- Variant interpretation -> Use `tooluniverse-variant-interpretation`44- Drug safety profiling -> Use `tooluniverse-adverse-event-detection`45- Disease-only analysis without spatial data -> Use `tooluniverse-multiomic-disease-characterization`46- GWAS analysis -> Use `tooluniverse-gwas-*` skills47- Bulk RNA-seq (non-spatial) -> Use `tooluniverse-systems-biology`4849---5051## Input Parameters5253| Parameter | Required | Description | Example |54|-----------|----------|-------------|---------|55| **svgs** | Yes | Spatially variable genes (gene symbols) | `['EGFR', 'CDH1', 'VIM', 'MYC', 'CD3E']` |56| **tissue_type** | Yes | Tissue/organ type | `brain`, `liver`, `lung`, `breast`, `skin` |57| **technology** | No | Spatial omics platform used | `10x Visium`, `MERFISH`, `DBiTplus`, `SLIDE-seq` |58| **disease_context** | No | Disease if applicable | `breast cancer`, `Alzheimer disease`, `liver cirrhosis` |59| **spatial_domains** | No | Dict mapping domain name to marker genes | `{'Tumor core': ['MYC','EGFR'], 'Stroma': ['VIM','COL1A1']}` |60| **cell_types** | No | Cell types identified in deconvolution | `['Epithelial', 'T cell', 'Macrophage', 'Fibroblast']` |61| **proteins** | No | Proteins detected (if multi-modal) | `['CD3', 'CD8', 'PD-L1', 'Ki67']` |62| **metabolites** | No | Metabolites detected (if SpatialMETA) | `['glutamine', 'lactate', 'ATP']` |6364---6566## Spatial Omics Integration Score (0-100)6768### Score Components6970**Data Completeness (0-30 points)**:71- SVGs provided (>10 genes): 5 points72- Disease context provided: 5 points73- Spatial domains defined: 5 points74- Cell type composition available: 5 points75- Multi-modal data (protein/metabolite): 5 points76- Literature context found: 5 points7778**Biological Insight (0-40 points)**:79- Significant pathway enrichment (FDR < 0.05): 10 points80- Cell-cell interaction predictions: 10 points81- Disease mechanism identified: 10 points82- Druggable targets found in disease regions: 10 points8384**Evidence Quality (0-30 points)**:85- Cross-database validation (gene found in 3+ databases): 10 points86- Clinical validation (approved drugs for spatial targets): 10 points87- Literature support (PubMed evidence for spatial patterns): 10 points8889### Score Interpretation9091| Score | Tier | Interpretation |92|-------|------|----------------|93| **80-100** | Excellent | Comprehensive spatial characterization, strong biological insights, druggable targets identified |94| **60-79** | Good | Good pathway and interaction analysis, some disease/therapeutic context |95| **40-59** | Moderate | Basic enrichment complete, limited spatial domain comparison or interaction analysis |96| **0-39** | Limited | Minimal data, gene-level annotation only |9798### Evidence Grading System99100| Tier | Symbol | Criteria | Examples |101|------|--------|----------|----------|102| **T1** | [T1] | Direct human evidence, clinical proof | FDA-approved drug for spatial target, validated biomarker |103| **T2** | [T2] | Experimental evidence | Validated spatial pattern in literature, known ligand-receptor pair |104| **T3** | [T3] | Computational/database evidence | PPI network prediction, pathway enrichment, expression correlation |105| **T4** | [T4] | Annotation/prediction only | GO annotation, text-mined association, predicted interaction |106107---108109## Report Template110111Create this file structure at the start: `{tissue}_{disease}_spatial_omics_report.md`112113```markdown114# Spatial Multi-Omics Analysis Report: {Tissue Type}115116**Report Generated**: {date}117**Technology**: {platform}118**Tissue**: {tissue_type}119**Disease Context**: {disease or "Normal tissue"}120**Total SVGs Analyzed**: {count}121**Spatial Domains**: {count}122**Spatial Omics Integration Score**: (to be calculated)123124---125126## Executive Summary127128(2-3 sentence synthesis of key spatial findings - fill after all phases complete)129130---131132## 1. Tissue & Disease Context133134### Tissue Information135| Property | Value | Source |136|----------|-------|--------|137| Tissue type | | |138| Disease | | |139| Expected cell types | | HPA |140141### Disease Identifiers (if applicable)142| System | ID | Source |143|--------|-----|--------|144145**Sources**: (tools used)146147---148149## 2. Spatially Variable Gene Characterization150151### 2.1 Gene ID Resolution152| Gene Symbol | Ensembl ID | Entrez ID | UniProt | Function | Source |153|-------------|------------|-----------|---------|----------|--------|154155### 2.2 Tissue Expression Patterns156| Gene | Tissue Expression | Specificity | Source |157|------|-------------------|-------------|--------|158159### 2.3 Subcellular Localization160| Gene | Location | Confidence | Source |161|------|----------|------------|--------|162163### 2.4 Disease Associations164| Gene | Disease | Score | Evidence | Source |165|------|---------|-------|----------|--------|166167**Sources**: (tools used)168169---170171## 3. Pathway Enrichment Analysis172173### 3.1 STRING Functional Enrichment174| Category | Term | Description | P-value | FDR | Genes | Source |175|----------|------|-------------|---------|-----|-------|--------|176177### 3.2 Reactome Pathway Analysis178| Pathway ID | Name | P-value | FDR | Genes Found | Total Genes | Source |179|------------|------|---------|-----|-------------|-------------|--------|180181### 3.3 GO Biological Processes182| GO Term | Description | P-value | FDR | Genes | Source |183|---------|-------------|---------|-----|-------|--------|184185### 3.4 GO Molecular Functions186| GO Term | Description | P-value | FDR | Genes | Source |187|---------|-------------|---------|-----|-------|--------|188189### 3.5 GO Cellular Components190| GO Term | Description | P-value | FDR | Genes | Source |191|---------|-------------|---------|-----|-------|--------|192193### Pathway Summary194- Top enriched pathways:195- Key biological processes:196- Spatial pathway implications:197198**Sources**: (tools used)199200---201202## 4. Spatial Domain Characterization203204### Domain: {domain_name}205206#### Marker Genes207| Gene | Function | Pathways | Source |208|------|----------|----------|--------|209210#### Enriched Pathways (domain-specific)211| Pathway | P-value | FDR | Genes | Source |212|---------|---------|-----|-------|--------|213214#### Cell Type Signature215| Cell Type | Marker Genes Present | Confidence |216|-----------|---------------------|------------|217218#### Biological Interpretation219(Narrative interpretation of this domain)220221(Repeat for each domain)222223### 4.N Domain Comparison224| Feature | Domain 1 | Domain 2 | Domain 3 |225|---------|----------|----------|----------|226| Top pathway | | | |227| Cell types | | | |228| Disease relevance | | | |229230**Sources**: (tools used)231232---233234## 5. Cell-Cell Interaction Inference235236### 5.1 Protein-Protein Interactions (STRING)237| Protein A | Protein B | Score | Type | Source |238|-----------|-----------|-------|------|--------|239240### 5.2 Ligand-Receptor Pairs241| Ligand | Receptor | Domain (Ligand) | Domain (Receptor) | Evidence | Source |242|--------|----------|-----------------|-------------------|----------|--------|243244### 5.3 Signaling Pathways245| Pathway | Components in Data | Spatial Distribution | Source |246|---------|--------------------|---------------------|--------|247248### 5.4 Interaction Network Summary249- Key interaction hubs:250- Cross-domain interactions:251- Predicted cell-cell communication axes:252253**Sources**: (tools used)254255---256257## 6. Disease & Therapeutic Context258259### 6.1 Disease Gene Overlap260| Gene | Disease Association Score | Evidence Type | Source |261|------|--------------------------|---------------|--------|262263### 6.2 Druggable Targets in Spatial Domains264| Gene | Domain | Tractability | Modality | Approved Drugs | Source |265|------|--------|-------------|----------|----------------|--------|266267### 6.3 Drug Mechanisms Relevant to Spatial Targets268| Drug | Target | Mechanism | Phase | Source |269|------|--------|-----------|-------|--------|270271### 6.4 Clinical Trials272| NCT ID | Title | Target Gene | Phase | Status | Source |273|--------|-------|-------------|-------|--------|--------|274275### Therapeutic Summary276- Druggable genes in disease regions:277- Approved therapies:278- Pipeline drugs:279- Novel opportunities:280281**Sources**: (tools used)282283---284285## 7. Multi-Modal Integration286287### 7.1 Protein-RNA Concordance (if protein data available)288| Gene/Protein | RNA Pattern | Protein Pattern | Concordance | Source |289|-------------|-------------|-----------------|-------------|--------|290291### 7.2 Subcellular Context292| Gene | mRNA Location (spatial) | Protein Location (HPA) | Concordance | Source |293|------|------------------------|----------------------|-------------|--------|294295### 7.3 Metabolic Context (if metabolomics available)296| Gene | Metabolic Pathway | Metabolites Detected | Spatial Pattern | Source |297|------|-------------------|---------------------|-----------------|--------|298299**Sources**: (tools used)300301---302303## 8. Immune Microenvironment (if relevant)304305### 8.1 Immune Cell Markers306| Cell Type | Marker Genes | Spatial Domain | Source |307|-----------|-------------|----------------|--------|308309### 8.2 Immune Checkpoint Expression310| Checkpoint | Gene | Expression Pattern | Source |311|------------|------|--------------------|--------|312313### 8.3 Tumor-Immune Interface (if cancer)314| Feature | Finding | Evidence | Source |315|---------|---------|----------|--------|316317### Immune Summary318- Immune infiltration pattern:319- Key immune checkpoints:320- Immunotherapy implications:321322**Sources**: (tools used)323324---325326## 9. Literature & Validation Context327328### 9.1 Literature Evidence329| PMID | Title | Relevance | Year | Source |330|------|-------|-----------|------|--------|331332### 9.2 Known Spatial Patterns333(Known tissue architecture/zonation from literature)334335### 9.3 Validation Recommendations336| Priority | Gene/Target | Method | Rationale |337|----------|-------------|--------|-----------|338| High | | IHC / smFISH | |339| Medium | | IF / ISH | |340341**Sources**: (tools used)342343---344345## Spatial Omics Integration Score346347| Component | Points | Max | Details |348|-----------|--------|-----|---------|349| SVGs provided | | 5 | |350| Disease context | | 5 | |351| Spatial domains | | 5 | |352| Cell types | | 5 | |353| Multi-modal data | | 5 | |354| Literature context | | 5 | |355| Pathway enrichment | | 10 | |356| Cell-cell interactions | | 10 | |357| Disease mechanism | | 10 | |358| Druggable targets | | 10 | |359| Cross-database validation | | 10 | |360| Clinical validation | | 10 | |361| Literature support | | 10 | |362| **TOTAL** | | **100** | |363364**Score**: XX/100 - [Tier]365366---367368## Completeness Checklist369370- [ ] Gene ID resolution complete371- [ ] Tissue expression patterns analyzed (HPA)372- [ ] Subcellular localization checked (HPA)373- [ ] Pathway enrichment complete (STRING + Reactome)374- [ ] GO enrichment complete (BP + MF + CC)375- [ ] Spatial domains characterized individually376- [ ] Domain comparison performed377- [ ] Protein-protein interactions analyzed (STRING)378- [ ] Ligand-receptor pairs identified379- [ ] Disease associations checked (OpenTargets)380- [ ] Druggable targets identified (OpenTargets tractability)381- [ ] Drug mechanisms reviewed382- [ ] Multi-modal integration performed (if data available)383- [ ] Immune microenvironment characterized (if relevant)384- [ ] Literature search completed385- [ ] Validation recommendations provided386- [ ] Spatial Omics Integration Score calculated387- [ ] Executive summary written388- [ ] All sections have source citations389390---391392## References393394### Data Sources Used395| # | Tool | Parameters | Section | Items Retrieved |396|---|------|------------|---------|-----------------|397398### Database Versions399- OpenTargets: (current)400- STRING: v12.0401- Reactome: (current)402- HPA: (current)403- GTEx: v10404```405406---407408## Phase 0: Input Processing & Disambiguation (ALWAYS FIRST)409410**Objective**: Parse user input, resolve tissue/disease identifiers, establish analysis context.411412### Tools Used413414**OpenTargets_get_disease_id_description_by_name** (if disease context provided):415- **Input**: `diseaseName` (string) - Disease name416- **Output**: `{data: {search: {hits: [{id, name, description}]}}}`417- **Use**: Get MONDO/EFO IDs for disease queries418419**OpenTargets_get_disease_description_by_efoId**:420- **Input**: `efoId` (string) - Disease ID (e.g., `MONDO_0007254`)421- **Output**: `{data: {disease: {id, name, description, dbXRefs}}}`422- **Use**: Get full disease description423424**HPA_search_genes_by_query** (tissue cell type context):425- **Input**: `query` (string) - Search term426- **Output**: List of gene entries matching query427- **Use**: Verify tissue-relevant genes428429### Workflow4304311. Parse SVG list from user input (ensure valid gene symbols)4322. Identify tissue type and map to standard ontology term4333. If disease provided, resolve to MONDO/EFO ID using OpenTargets4344. Get disease description and cross-references4355. Determine analysis scope:436 - Cancer? -> Include immune microenvironment, somatic mutations, druggable targets437 - Neurological? -> Include brain region specificity, neuronal markers438 - Metabolic? -> Include metabolic zonation, enzyme distribution439 - Normal tissue? -> Focus on tissue architecture and cell type composition4406. Set up report file with header information441442### Decision Logic443444- **Cancer tissue**: Enable immune microenvironment phase, CIViC/cBioPortal queries, immuno-oncology analysis445- **Normal tissue**: Skip disease phases, focus on tissue zonation and cell type composition446- **Liver/kidney/brain**: Enable zonation-specific analysis447- **No disease context**: Proceed with tissue biology only448- **Small gene list (<20)**: Warn about limited enrichment power, emphasize gene-level analysis449- **Large gene list (>500)**: Suggest filtering to top SVGs by significance before enrichment450451---452453## Phase 1: Gene Characterization454455**Objective**: Resolve gene identifiers, annotate functions, tissue specificity, and subcellular localization.456457### Tools Used458459**MyGene_query_genes** (gene ID resolution):460- **Input**: `query` (string) - Gene symbol461- **Output**: `{hits: [{_id, symbol, name, ensembl: {gene}, entrezgene}]}`462- **Use**: Resolve gene symbol to Ensembl ID, Entrez ID463- **NOTE**: First hit may not be exact match - filter by `symbol` field464465**UniProt_get_function_by_accession** (gene function):466- **Input**: `accession` (string) - UniProt accession467- **Output**: List of function description strings468- **Use**: Get protein function annotation469470**UniProt_get_subcellular_location_by_accession** (protein localization):471- **Input**: `accession` (string)472- **Output**: Subcellular location information473- **Use**: Where the protein is located in the cell474475**HPA_get_subcellular_location** (validated localization):476- **Input**: `gene_name` (string) - Gene symbol477- **Output**: `{gene_name, main_locations: [], additional_locations: [], location_summary}`478- **Use**: Experimentally validated protein subcellular location479480**HPA_get_rna_expression_by_source** (tissue expression):481- **Input**: `gene_name` (string), `source_type` (string: 'tissue'), `source_name` (string)482- **Output**: `{data: {gene_name, source_type, source_name, expression_value, expression_level}}`483- **Use**: Check expression in the specific tissue of interest484- **NOTE**: All 3 parameters are REQUIRED485486**HPA_get_comprehensive_gene_details_by_ensembl_id** (full HPA data):487- **Input**: `ensembl_id` (string), `include_isoforms` (bool), `include_images` (bool), `include_antibodies` (bool), `include_expression` (bool) - ALL 5 parameters REQUIRED488- **Output**: `{ensembl_id, gene_name, uniprot_ids, summary, protein_classes, tissue_expression, cell_line_expression, ...}`489- **Use**: One-stop gene characterization from HPA490- **NOTE**: Use `include_expression=True` for tissue data; set others to `False` for faster response491492**HPA_get_cancer_prognostics_by_gene** (cancer prognosis):493- **Input**: `ensembl_id` (string) - Ensembl gene ID (NOT gene_name)494- **Output**: `{gene_name, prognostic_cancers_count, prognostic_summary: [{cancer_type, prognostic_type, p_value}]}`495- **Use**: Prognostic significance in cancer (if cancer context)496497**UniProtIDMap_gene_to_uniprot** (ID mapping):498- **Input**: `gene_name` (string), `organism` (string, default 'human')499- **Output**: UniProt accession for the gene500- **Use**: Map gene symbol to UniProt accession501502### Workflow5035041. For each SVG (batch if >20, sample top genes):505 a. Query MyGene to get Ensembl ID, Entrez ID506 b. Map to UniProt accession507 c. Get subcellular location from HPA508 d. Get tissue expression from HPA509 e. If cancer: check cancer prognostics5102. Compile gene characterization table5113. Identify genes with tissue-specific expression5124. Note genes with nuclear vs membrane vs secreted localization (relevant for spatial patterns)513514### Batch Strategy for Large Gene Lists515516- **10-50 genes**: Characterize all individually517- **50-200 genes**: Characterize top 50 by priority (known disease genes first), summarize rest518- **200+ genes**: Characterize top 30, use enrichment for the full list519- Always run pathway enrichment on the FULL list regardless520521---522523## Phase 2: Pathway & Functional Enrichment524525**Objective**: Identify biological pathways and functions enriched in SVGs and per-domain gene sets.526527### Tools Used528529**STRING_functional_enrichment** (primary enrichment):530- **Input**: `protein_ids` (array of gene symbols), `species` (int, 9606 for human)531- **Output**: `{status: 'success', data: [{category, term, number_of_genes, number_of_genes_in_background, p_value, fdr, description, inputGenes, preferredNames}]}`532- **Use**: Comprehensive enrichment across GO, KEGG, Reactome, COMPARTMENTS, DISEASES533- **Categories**: `Process` (GO:BP), `Function` (GO:MF), `Component` (GO:CC), `KEGG`, `Reactome`, `COMPARTMENTS`, `DISEASES`, `Keyword`, `PMID`534- **NOTE**: This is the PRIMARY enrichment tool. Returns all categories in one call535536**ReactomeAnalysis_pathway_enrichment** (Reactome-specific):537- **Input**: `identifiers` (string, space-separated gene symbols, NOT array)538- **Output**: `{data: {token, pathways_found, pathways: [{pathway_id, name, p_value, fdr, entities_found, entities_total}]}}`539- **Use**: Detailed Reactome pathway analysis with hierarchy540- **NOTE**: identifiers is a SPACE-SEPARATED STRING, not array541542**Reactome_map_uniprot_to_pathways** (individual gene):543- **Input**: `id` (string) - UniProt accession544- **Output**: Plain list of pathway objects (no data wrapper)545- **Use**: Map individual proteins to Reactome pathways546547**GO_get_annotations_for_gene** (individual gene GO):548- **Input**: `gene_id` (string) - Gene symbol or ID549- **Output**: Plain list of GO annotation objects550- **Use**: Get GO annotations for individual genes551552**kegg_search_pathway** (KEGG pathway search):553- **Input**: `query` (string) - Pathway name or keyword554- **Output**: Pathway search results555- **Use**: Find KEGG pathways relevant to spatial findings556557**WikiPathways_search** (WikiPathways):558- **Input**: `query` (string) - Search term559- **Output**: WikiPathways search results560- **Use**: Additional pathway context561562### Workflow5635641. **Global SVG enrichment**: Run STRING_functional_enrichment on ALL SVGs565 - Filter results by FDR < 0.05566 - Separate by category (Process, Function, Component, KEGG, Reactome)567 - Report top 10-15 per category5682. **Reactome detailed analysis**: Run ReactomeAnalysis_pathway_enrichment569 - Report top pathways with FDR < 0.055703. **Per-domain enrichment** (if spatial domains provided):571 - Run STRING_functional_enrichment on each domain's gene set572 - Compare enriched pathways across domains573 - Identify domain-specific vs shared pathways5744. **Compile pathway tables**: Merge results from all enrichment tools575576### Enrichment Interpretation577578- **Signaling pathways** (RTK, Wnt, Notch, Hedgehog): Cell-cell communication579- **Metabolic pathways**: Tissue metabolic zonation580- **Immune pathways**: Immune infiltration/exclusion581- **ECM/adhesion pathways**: Tissue structure and remodeling582- **Cell cycle/proliferation**: Growth zones583- **Apoptosis/stress**: Damage zones584585---586587## Phase 3: Spatial Domain Characterization588589**Objective**: Characterize each spatial domain biologically and compare between domains.590591### Tools Used592593Uses the same tools as Phase 2 (STRING_functional_enrichment, ReactomeAnalysis) applied per-domain, plus:594595**HPA_get_biological_processes_by_gene** (per-gene processes):596- **Input**: `gene_name` (string)597- **Output**: Biological processes associated with the gene598- **Use**: Annotate domain marker genes599600**HPA_get_protein_interactions_by_gene** (gene interactions):601- **Input**: `gene_name` (string)602- **Output**: Known protein interaction partners603- **Use**: Build domain-specific interaction context604605### Workflow6066071. For each spatial domain:608 a. Get marker gene list609 b. Run STRING_functional_enrichment on domain genes610 c. Identify top pathways, GO terms611 d. Assign likely cell type(s) based on marker genes:612 - Epithelial: CDH1, EPCAM, KRT18, KRT19613 - Mesenchymal/Fibroblast: VIM, COL1A1, COL3A1, FAP, ACTA2614 - Immune T cell: CD3E, CD3D, CD4, CD8A, CD8B615 - Immune B cell: CD19, CD20 (MS4A1), CD79A616 - Macrophage: CD68, CD163, CSF1R617 - Endothelial: PECAM1, VWF, CDH5618 - Neuronal: SNAP25, SYP, MAP2, NEFL619 - Hepatocyte: ALB, HNF4A, CYP3A4620 e. Generate biological interpretation narrative6212. Compare domains:622 - Differential pathways623 - Unique vs shared genes624 - Disease-relevant vs homeostatic regions625 - Transition zones (shared genes between adjacent domains)626627### Cell Type Assignment Rules628629When user does not provide cell type annotations, infer from marker genes:630- Check each gene against known cell type markers631- Use HPA tissue/cell type expression data for validation632- Report confidence level (high: 3+ markers match, medium: 2 markers, low: 1 marker)633634---635636## Phase 4: Cell-Cell Interaction Inference637638**Objective**: Predict cell-cell communication from spatial gene expression patterns.639640### Tools Used641642**STRING_get_interaction_partners** (PPI network):643- **Input**: `protein_ids` (array), `species` (int, 9606), `limit` (int), `confidence_score` (float, 0.7)644- **Output**: `{status: 'success', data: [{preferredName_A, preferredName_B, score, nscore, fscore, pscore, ascore, escore, dscore, tscore}]}`645- **Use**: Find protein-protein interactions among SVGs646- **Score types**: nscore=neighborhood, fscore=fusion, pscore=phylogenetic, ascore=coexpression, escore=experimental, dscore=database, tscore=textmining647648**STRING_get_protein_interactions** (pairwise interactions):649- **Input**: `protein_ids` (array), `species` (int, 9606)650- **Output**: Interaction data between specified proteins651- **Use**: Get interactions within a specific gene set652653**intact_search_interactions** (IntAct database):654- **Input**: `query` (string), `max` (int)655- **Output**: Interaction data from IntAct656- **Use**: Complement STRING with IntAct interactions657658**Reactome_get_interactor** (Reactome interactions):659- **Input**: Protein/gene identifier660- **Output**: Reactome interaction data661- **Use**: Pathway-level interaction context662663**DGIdb_get_drug_gene_interactions** (drug-gene interactions):664- **Input**: `genes` (array of strings)665- **Output**: Drug-gene interaction data666- **Use**: Identify druggable interaction nodes667668### Ligand-Receptor Analysis669670Known ligand-receptor pairs to check in SVG list:671- **Growth factors**: EGF-EGFR, HGF-MET, VEGF-KDR, FGF-FGFR, PDGF-PDGFRA/B672- **Cytokines**: TNF-TNFR, IL6-IL6R, IFNG-IFNGR, TGFB1-TGFBR1/2673- **Chemokines**: CXCL12-CXCR4, CCL2-CCR2, CXCL10-CXCR3674- **Immune checkpoints**: CD274(PD-L1)-PDCD1(PD-1), CD80/CD86-CTLA4, LGALS9-HAVCR2(TIM-3)675- **Notch signaling**: DLL1/3/4-NOTCH1/2/3/4, JAG1/2-NOTCH1/2676- **Wnt signaling**: WNT ligands-FZD receptors677- **Adhesion**: CDH1-CDH1 (homotypic), ITGA/B integrins-ECM678- **Hedgehog**: SHH-PTCH1679680### Workflow6816821. Run STRING_get_interaction_partners on all SVGs683 - Filter interactions with score > 0.7684 - Identify hub genes (most connections)6852. Check for known ligand-receptor pairs in gene list686 - Cross-reference with spatial domain assignments687 - Identify potential cross-domain signaling6883. Build interaction network:689 - Intra-domain interactions (within same spatial region)690 - Inter-domain interactions (between different regions)691 - Identify signaling axes (e.g., tumor-stroma, immune-tumor)6924. Map interactions to Reactome signaling pathways693694---695696697---698699> **Extended Reference**: For detailed tool tables, examples, and templates, read `REFERENCE.md` in this skill directory.700> The agent can access it via: `read skills/tooluniverse-spatial-omics-analysis/REFERENCE.md`